Viatris Rebounds from Key Moving Averages as Uptrend ContinuesViatris, Inc.BATS:VTRSfinvestnomicsVTRS is rebounding from a retracement after finding support at its 20-day and 50-day moving averages. The stock continues to make higher highs and higher lows. Viatris Inc. is a $19.60 billion market-cap global healthcare company engaged in the development and distribution of pharmaceutical and healthcare products. The company offers medicines across multiple therapeutic areas, including cardiovascular disease, oncology, dermatology, eye care, gastroenterology, immunology, and women's health. Viatris operates through four segments: Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets, giving it a broad international footprint across both mature and developing economies. VTRS is a no-moat company, reflecting the competitive nature of the generic and specialty pharmaceutical industry. The company has delivered revenue growth in each of the last three quarters, while EPS increased in two of the last three quarters. Operating and net margins stand at 10% and 5%, respectively. ROE and ROIC are currently negative at -2% and -1%, highlighting profitability challenges, while the balance sheet remains supported by a current ratio of 1.5x and a debt-to-equity ratio of 1.0x.